Vaccine Production Facility

Client
Shionogi & Co., Ltd.
Location
Ikeda-cho, Ibi District, Gifu Prefecture, Japan Within UNIGEN Gifu Plant
Scope of Work
Engineering, Procurement, Construction and Validation (E.P.C.V)
Year of completion
2023
地図画像
メイン画像
Exterior View of Vaccine Manufacturing Facility

Establishing Domestic Vaccine Commercial Production

Significant National Project for Domestic Vaccine Supply

This project is to establish commercial production of a recombinant protein vaccine using the unique Baculovirus Expression Vector System (BEVS) technology, possessed by the group company of Shionogi & Co., Ltd, and holds great social significance in contributing towards establishing a domestic vaccine manufacturing facility, addressing Japan's reliance on vaccine imports and ensuring a stable supply of domestically produced vaccines.

Leveraging our Extensive Experience in the Pharmaceutical Field

Chiyoda has constructed more than 630 pharmaceutical plants in over 60 years. Leveraging on this expertise, we successfully completed a manufacturing facility of drug substance for vaccine for Shionogi & Co., Ltd. in January 2023. The first manufacturing line was completed within a tight 8 month time schedule from the start of construction in August 2020. The second manufacturing line and associated facilities were also completed on schedule, showcasing our group’s technical expertise and project management capabilities.

Strengthening our Track Record

We will continue expanding upon the success of this project with further ventures into the growing fields of biopharmaceuticals, including cell therapy and regenerative medicine, as well as the broader biotechnology industry.

To the Projects main page